Q-omics provides the consensus-scored MTERF4 profile across patient tissues and cancer cell-line models. MTERF4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTERF4 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MTERF4 RNA expression shows 20,858 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where MTERF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTERF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTERF4 survival associations across molecular data types. MTERF4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTERF4 RNA expression–survival associations across cancer types. High MTERF4 expression shows unfavorable associations in ACC, LIHC, KIRP and CESC, but favorable associations in KIRC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTERF4 RNA expression.
This table summarizes MTERF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTERF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTERF4 shows lower tumor expression in THCA, KICH, LUSC, UCEC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher MTERF4 RNA expression in normal versus tumor tissue (log2 FC = −1.391, t-test p < 0.001).
This table shows molecular features associated with MTERF4 in patient tissues and cancer cell lines. In patient samples, MTERF4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTERF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
